Tag: antibody-based therapies

June 6, 2018

argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment...
May 9, 2018

argenx reports first quarter 2018 financial results and provides business update

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment...
March 22, 2018

argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117

argenx (Nasdaq:ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune...
March 31, 2017

argenx Doses First Patient in ARGX-113 Study

argenx (EBR:ARGX) announced the dosing of the first patient in a Phase II proof-of-concept study for ARGX-113 in patients with...